Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI

• Status: Unknown status
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a retrospective, randomized, parallel, open-labeled, controlled study to find out whether STEMI patients undergoing emergency PCI can benefit from intensive atorvastatin treatment compared with routine treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Chao Yang Hospital
• Collaborator: Pfizer
• Treatments: Atorvastatin; Atorvastatin Calcium; Hydroxymethylglutaryl-CoA Reductase Inhibitors

Criteria

Inclusion Criteria:

• 20-75 years old

• myocardiac ischemia symptom of index event appeared less than 12 hours before enrollment.

• ECG showed elevated ST segment in 3 or more contiguous leads

• diagnosed with acute STEMI

• eligible for primary PCI, and primary PCI is scheduled within 2 hours after enrollment

Exclusion Criteria:

• allergic or experienced serious adverse reaction to HMG-CoA reductase

• pregnancy, lactation, or child bearing potential women without any effective contraception

• accompanied with malignant disease

• active hepatic disease or hepatic dysfunction